GLS inhibitors, such as CB-839, have been shown to impair GSC survival by inducing metabolic stress and triggering the amino acid deprivation response pathway, thereby increasing their susceptibility to chemotherapy.489 While clinical evidence supporting this finding remains limited, dual inhibition strategies targeting key CSC metabolic pathways hold significant promise for improving cancer treatment. The gene discussed is GLS; the disease is cancer.